Urine Biomarkers: Real-World Implementation in Clinical Practice

Disclosures: Both speakers received honoraria for their participation in this webinar. 

Witjes is an advisor/lecturer for BMS, Medac, Thermosome, CAPS, Combat, JeMedis, Photocure, Astellas, MEL, Sanofi Pasteur Canada, Nucleix Israel, and Spectrum Pharma; and has received financial support from Ipsen. 

Guerrero Ramos is an employee of SERMAS (Servicio Madrileño de Salud); has received research support as a principal investigator from Johnson & Johnson, Pfizer, Taris, Bristol Myers Squibb, Roche, Seagen, AstraZeneca, Combat Medical, Cepheid, Fidia, Astellas, UroGen, MSD, and enGene; served as a consultant for Johnson & Johnson, Pfizer, Merck, Roche, Taris, Combat Medical, AstraZeneca, MSD, Bristol Myers Squibb, enGene, and Nanobots Therapeutics; served on scientific advisory boards for AstraZeneca, Bristol Myers Squibb, Combat Medical, Johnson & Johnson, Nucleix, Pfizer, Taris, Roche, MSD, and enGene; received manuscript support from Pfizer, Janssen, Combat Medical, AstraZeneca, Johnson & Johnson, and Bristol Myers Squibb; participated in speaker bureaus for Janssen, Nucleix, MSD, Pfizer, Merck, Bristol Myers Squibb, AstraZeneca, Palex, Combat Medical, Johnson & Johnson, and Recordati; and received travel support from Pfizer, Recordati, Ipsen, Combat Medical, Alter, Salvat, Nucleix, AstraZeneca, Fidia, and Johnson & Johnson; and holds stock in CG Oncology, Johnson & Johnson, and Pfizer.